ReviewPlant physiology2025
Genome modification in plant mitochondria.
Review in Plant physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Harnessing mitochondrial genome editing for crop improvement: principles and applications.aBIOTECH · 2026Review
- Crops exposed to extreme conditions: perspectives of gene editing to improve stress tolerance.Plant cell reports · 2026Review
- CRISPR-Cas9 and next-generation gene editing strategies for therapeutic intervention of neurodegenerative pathways in Alzheimer's disease: a state-of-the-art review.Acta neurologica Belgica · 2026Review
- Multipartite mitochondrial genome evolution in Halophila seagrasses: repeat-driven structural plasticity and selection signatures of marine adaptation.BMC plant biology · 2026Article
- The complete mitochondrial genome and phylogenetic analysis ofFrontiers in plant science · 2026Article
- Mitochondrial genome ofFrontiers in plant science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Mitochondria are an indispensable component of every plant cell and are inextricably linked to many vital functions. One of their key characteristics is that they have their own genome. This genome, although greatly reduced, encodes several essential genes. While this has been known for decades, until recently it has not been possible to study the mitochondrial genome and its function in detail due to the lack of suitable tools for forward and reverse genetics. This is partly due to the low mutation rate in mitochondria and the lack of methods for direct transformation. A breakthrough came with the use of nuclear encoded transcription activator-like effector (TALE) nucleases (TALENs) for targeted mitochondrial mutagenesis. One of the first applications was to unambiguously show that certain ORFs were causal for cytoplasmic male sterility (CMS). This had previously been beyond our technical capabilities. TALENs are suitable for all plant species amenable to nuclear transformation because they are protein-only and can be imported post-transcriptionally into the mitochondria. Unfortunately, TALEN mutagenesis in plant mitochondria often seems to be associated with large genomic rearrangements. DNA base editors, the latest addition to the toolbox, bypass these side effects and merely introduce point mutations. They are based on TALEs and could only be developed after the discovery of a cytosine deaminase that acts on double-stranded DNA. The possibilities for targeted modification of the mitochondrial genome in plants are developing rapidly. This article aims to show where we stand in this development and what we can expect in the near future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.